A kind of synthetic method of fenofibrate impurity

A two-step synthesis of fenofibrate impurity using esterification and ester exchange reactions addresses the synthesis gap, providing high-quality impurity reference substances efficiently and cost-effectively, enhancing fenofibrate quality control.

CN118652173BActive Publication Date: 2024-12-06GUANGZHOU CATO RES CHEM INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411139983.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-12-06
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

There is a lack of a cost-effective and efficient method for synthesizing the fenofibrate impurity 1-isopropoxy-2-methyl-1-oxopropane-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate, which is crucial for drug quality control, as no literature reports on its synthesis exist.

Method used

A two-step process involving esterification and ester exchange reactions using 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionic acid as a starting material, employing condensing agents and bases like 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and cesium carbonate, to produce the fenofibrate impurity.

Benefits of technology

The method provides high-quality impurity reference substances at low cost with minimal by-products, short preparation time, and environmental friendliness, addressing the synthesis gap and enhancing fenofibrate quality control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118652173B_ABST
    Figure CN118652173B_ABST
Patent Text Reader

Abstract

The invention discloses a method for synthesizing fenofibrate impurities, comprising the following steps: an esterification reaction of a structural compound shown in formula I and methyl 2-hydroxyisobutyrate to obtain a structural compound shown in formula II; an ester exchange reaction of a structural compound shown in formula II and isopropanol to obtain a structural compound shown in formula III, i.e., a fenofibrate impurity. The present invention has the characteristics of cheap and easy-to-obtain raw materials, short preparation cycle, few by-products, and environmentally friendly and pollution-free, provides a new method for the preparation of fenofibrate impurities, and its purity also fully meets the requirements of impurity reference substances, and plays a significant role in the quality research of fenofibrate impurities.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of synthesis of impurity reference substances, in particular to the synthesis of fenofibrate impurities. Background Art

[0002] Fenofibrate is called Fenofibrate in English, and its chemical name is 2-methyl-2-(4-(4-chlorobenzoyl)phenoxy)propionic acid isopropyl ester. The pure product is white or off-white crystalline powder, odorless and tasteless. Fenofibrate is highly soluble in chloroform, easily soluble in acetone or ether, slightly soluble in ethanol, and almost insoluble in water. Fenofibrate is mainly used to lower cholesterol levels in patients at risk of cardiovascular disease; like other fibrates, fenofibrate lowers low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) levels, and can increase high-density lipoprotein (HDL) levels and lower triglyceride (TG) levels. Fenofibrate can be used alone or in combination with statins to treat hypercholesterolemia and hypertriglyceridemia. Fenofibrate has been used since 1975 and is one of the most commonly used fibrates with good efficacy and tolerability. Fenofibrate structure

[0003] 1-isopropoxy-2-methyl-1-oxopropan-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate, whose English name is 1-isopropoxy-2-methyl-1-oxopropan-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate, is an important impurity of fenofibrate. It is included in the European Pharmacopoeia Reference Standard List, corresponding to Fenofibrate impurity G CRS. The detection of impurity content in drugs is very important for drug quality control. The detection of impurity content requires corresponding impurity reference substances, but there is no literature report on the synthesis and preparation of this type of impurity, which makes it difficult to provide cheap, easy-to-obtain, high-quality impurity reference substances for quality control-related research on fenofibrate. Summary of the invention

[0004] The object of the present invention is to provide a method for synthesizing fenofibrate impurities, so as to solve the problem of blank technology for preparing 1-isopropoxy-2-methyl-1-oxopropane-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate in the prior art.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions:

[0006] A method for preparing fenofibrate impurities comprises the following steps:

[0007] (1) an esterification reaction is carried out between the compound of formula I and methyl 2-hydroxyisobutyrate to obtain a compound of formula II;

[0008] (2) The compound of formula II and isopropanol undergo an ester exchange reaction to obtain a compound of formula III as the target product;

[0009] The structural compound represented by formula I, the structural compound represented by formula II, and the structural compound represented by formula III are as follows:

[0010]

[0011] Formula I Formula II

[0012] Formula III.

[0013] Furthermore, in the step (1), the compound of the structure represented by formula I and methyl 2-hydroxyisobutyrate undergo an esterification reaction under the conditions of a condensing agent and a base;

[0014] In the step (2), the compound of formula II and isopropanol undergo an ester exchange reaction under alkaline conditions.

[0015] Furthermore, in the step (1), the condensing agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and the base is 4-dimethylaminopyridine;

[0016] In the step (2), the base is at least one of cesium carbonate and potassium carbonate.

[0017] Furthermore, in the step (1), the initial concentration of the compound of the structure represented by formula I is 0.1 to 1 mol / L.

[0018] Furthermore, in step (1), the initial concentration of the compound of the structure represented by formula I is 0.4-0.6 mol / L.

[0019] Furthermore, in the step (1), the amount of the condensing agent used is 1.0 to 3.0 equivalents of the molar amount of the compound of the structure shown in Formula I, the amount of the base used is 0.05 to 1.0 equivalents of the molar amount of the compound of the structure shown in Formula I, and the amount of methyl 2-hydroxyisobutyrate used is 1.0 to 2.0 equivalents of the molar amount of the compound of the structure shown in Formula I.

[0020] Furthermore, in the step (1), the amount of the condensing agent used is 1.5 to 2.5 equivalents of the molar amount of the compound of the structure shown in formula I, the amount of the base used is 0.1 to 0.3 equivalents of the molar amount of the compound of the structure shown in formula I, and the amount of methyl 2-hydroxyisobutyrate used is 1.0 to 1.5 equivalents of the molar amount of the compound of the structure shown in formula I.

[0021] Furthermore, in the step (2), the compound of structure represented by formula II is dissolved in isopropanol, the initial concentration of the compound of structure represented by formula II is 0.1-1 mol / L, and the amount of base used is 1.0-4.0 equivalents of the molar amount of the compound of structure represented by formula II.

[0022] Furthermore, in the step (2), the compound of the structure represented by formula II is dissolved in isopropanol, and the initial concentration of the compound of the structure represented by formula II is 0.2-0.4 mol / L.

[0023] Furthermore, in the step (2), the base is a mixture of cesium carbonate and potassium carbonate, and the molar ratio of cesium carbonate, potassium carbonate and the compound of the structure represented by formula II is 1:1:1 to 2:2:1.

[0024] Furthermore, in the step (1), the compound of formula I, a condensing agent, a base and a solvent are mixed at room temperature, stirred for 5 to 60 minutes, and finally methyl 2-hydroxyisobutyrate is added, and the mixture is stirred at room temperature for 8 to 24 hours;

[0025] In the step (2), the compound of the structure represented by formula II is dissolved in isopropanol, a base is added, and the mixture is heated to react to obtain the compound of the structure represented by formula III.

[0026] Furthermore, in the step (1), the compound of formula I, a condensing agent, a base and a solvent are mixed at room temperature, stirred for 10 to 30 minutes, and finally methyl 2-hydroxyisobutyrate is added and stirred at room temperature for a certain time, which is 10 to 16 hours.

[0027] Furthermore, the solvent in step (1) is dichloromethane.

[0028] Furthermore, in step (2), the system is heated to react at a temperature of 30 to 80° C., and the reaction time is 4 to 24 hours.

[0029] Furthermore, in the step (2), the system is heated to react at a temperature of 40 to 60° C., and the reaction time is 8 to 16 hours.

[0030] The present invention also provides application of the fenofibrate impurities obtained by the preparation method in preparing impurity reference substances.

[0031] The advantages of the present invention include: aiming at the blank of the existing fenofibrate impurity synthesis and preparation technology, the present invention provides a new synthesis route, using 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionic acid (structural compound shown in formula I) as a raw material, and obtaining fenofibrate impurity through two steps of esterification and transesterification, namely 1-isopropoxy-2-methyl-1-oxopropane-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate, whose English name is 1-isopropoxy-2-methyl-1-oxopropan-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate; the synthesis method has easy-to-obtain raw materials, low cost, few steps, short preparation cycle, few by-products, high total yield of the route, environmental protection and no pollution, and fills the blank of fenofibrate impurity preparation technology. It can provide a cheap and high-quality impurity reference substance for fenofibrate quality research, which is of great significance to the safe use of fenofibrate. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The drawings described herein are used to provide a further understanding of the present invention, constitute a part of the present application, and do not constitute an improper limitation of the present invention. In the drawings:

[0033] Figure 1 It is the one-dimensional H-NMR spectrum of the compound with the structure shown in Formula II.

[0034] Figure 2 The product mass spectrum of the structural compound shown in formula II.

[0035] Figure 3 This is the one-dimensional H-NMR spectrum of the compound with the structure shown in Formula III.

[0036] Figure 4 The product mass spectrum of the structural compound shown in formula III.

[0037] Figure 5 The product HPLC spectrum of the compound with the structure shown in formula III is shown in FIG. DETAILED DESCRIPTION

[0038] The present invention will be described in detail below in conjunction with the accompanying drawings and specific embodiments. The exemplary embodiments and descriptions of the present invention are used to explain the present invention, but are not intended to limit the present invention.

[0039] The present invention provides a method for synthesizing fenofibrate impurities, wherein the present invention uses a compound of structure shown in formula I as a starting material, synthesizes a compound of structure shown in formula II through esterification, and then synthesizes a compound of structure shown in formula III through ester exchange. Unless otherwise specified, the reagents used in the present invention are all commonly used reagents purchased from the market, and the operating temperatures involved, unless otherwise specified, are all carried out at room temperature of 25 to 28°C.

[0040] Among them, the structural compound represented by formula I, the structural compound represented by formula II, and the structural compound represented by formula III are as follows:

[0041]

[0042] Formula I Formula II

[0043] Formula III

[0044] The structural compound shown in formula I is 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionic acid, which is a commercially available raw material;

[0045] Other raw materials including methyl 2-hydroxyisobutyrate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 4-dimethylaminopyridine, potassium carbonate, cesium carbonate and isopropanol can be obtained from commercial sources;

[0046] The compound of the structure shown in formula II has a chemical name of 1-methoxy-2-methyl-1-oxopropan-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate, and its English name is: 1-methoxy-2-methyl-1-oxopropan-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate. The compound of the structure shown in formula II is synthesized independently by the inventors, and the synthesis route is as follows:

[0047]

[0048] The compound of the structure shown in Formula III is a fenofibrate impurity, and its chemical name is 1-isopropoxy-2-methyl-1-oxopropan-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate, and its English name is 1-isopropoxy-2-methyl-1-oxopropan-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate.

[0049] The synthetic reaction process of the present invention is as follows:

[0050]

[0051] The present application is further described in detail below in conjunction with specific embodiments. These embodiments should not be construed as limiting the scope of protection claimed in the present application.

[0052] Preparation of the structural compound shown in formula II Example 1

[0053] Take a dry reaction container, add the compound of formula I (5.00 g, 15.69 mmol, 1.00 eq), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (6.00 g, 31.37 mmol, 2.00 eq), 4-dimethylaminopyridine (0.38 g, 3.14 mmol, 0.20 eq) and dichloromethane (32.00 mL, C=0.50 M) in sequence, the powder is dissolved and clarified, stirred at room temperature for 10 min, 2-hydroxyisobutyric acid methyl ester (2.00 mL, 17.25 mmol, 1.10 eq) is added, and the reaction is carried out at room temperature for 12 h. After the reaction is completed by TLC monitoring, 30 mL of water is added to terminate the reaction, and then dichloromethane is used for extraction (30 mL*3), the organic phases are combined, saturated sodium chloride is added for extraction (15 mL*2), the organic phase is taken and dried with anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a yellow oily crude product. The crude product was separated and purified by silica gel column chromatography with petroleum ether and ethyl acetate as the mobile phase, wherein the volume ratio of petroleum ether to ethyl acetate was 6:1, to obtain a compound of formula II as a white solid (3.5 g) with a yield of 53%.

[0054] Take a dry reaction container, add the structural compound shown in formula II (3. 5g, 8.36mmol, 1.00 eq) and isopropanol (33.00 mL, C=0.25 M), add cesium carbonate (2.72 g, 8.36 mmol, 1.00 eq) and potassium carbonate (1.16 g, 8.36 mmol, 1.00 eq), and heat at 55°C for 12h. After the reaction is completed by TLC monitoring, the solvent is removed by vacuum concentration to obtain a yellow oily crude product. The crude product is separated and purified by silica gel column chromatography, and the mobile phase is petroleum ether and ethyl acetate, wherein the volume ratio of petroleum ether to ethyl acetate is 10:1, and the structural compound shown in formula III is obtained, 1.3 g of white solid, the yield is 35%, and the HPLC purity is 96.4%. Example 2

[0055] Take a dry reaction container, add the compound of formula I (5.00 g, 15.69 mmol, 1.00 eq), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (4.87 g, 31.37 mmol, 2.00 eq), 4-dimethylaminopyridine (0.38 g, 3.14 mmol, 0.20 eq) and dichloromethane (32.00 mL, C=0.50 M) in sequence, the powder is dissolved and clarified, stirred at room temperature for 10 min, 2-hydroxyisobutyric acid methyl ester (2.00 mL, 17.25 mmol, 1.10 eq) is added, and the reaction is carried out at room temperature for 12 h. After the reaction is completed by TLC monitoring, 30 mL of water is added to terminate the reaction, and then dichloromethane is used for extraction (30 mL*3), the organic phases are combined, saturated sodium chloride is added for extraction (15 mL*2), the organic phase is taken and dried with anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a yellow oily crude product. The crude product was separated and purified by silica gel column chromatography with petroleum ether and ethyl acetate as the mobile phase, wherein the volume ratio of petroleum ether to ethyl acetate was 6:1, to obtain a compound of formula II as a white solid (3.6 g) with a yield of 55%.

[0056] Take a dry reaction container, add the structural compound shown in formula II (3. 5g, 8.36mmol, 1.00 eq) and isopropanol (33.00 mL, C=0.25 M), add cesium carbonate (2.72 g, 8.36 mmol, 1.00 eq), and heat at 55°C for 16h. After the reaction is completed by TLC monitoring, the solvent is removed by concentration under reduced pressure to obtain a yellow oily crude product. The crude product is separated and purified by silica gel column chromatography, and the mobile phase is petroleum ether and ethyl acetate, wherein the volume ratio of petroleum ether to ethyl acetate is 10:1, and the structural compound shown in formula III is obtained, 1.0 g of white solid, the yield is 27%, and the HPLC purity is 95.3%.

[0057] The characterization data of the compound of the structure shown in formula II are as follows Figure 1-2 shown.

[0058] The H NMR spectrum of the compound of formula II: 1 H NMR (400 MHz, CDCl3) δ7.78–7.71(m,4H), 7.49–7.45(m,2H), 6.96–6.93(m,2H), 3.77 (s, 3H),1.70 (s, 6H),1.57 (s, 6H).

[0059] The characterization data of the compound of formula III are as follows Figure 3-5 shown.

[0060] The H NMR spectrum of the compound of formula III:1 H NMR (400 MHz, CDCl3) δ7.77–7.72(m ,4H), 7.47 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 5.13–5.04 (m ,1H), ,1.70 (s, 6H), 1.55 (s, 6H), 1.27 (d, J = 6.3 Hz, 6H).

[0061] The technical solutions provided by the embodiments of the present invention are introduced in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the embodiments of the present invention. The description of the above embodiments is only applicable to help understand the principles of the embodiments of the present invention. At the same time, for those skilled in the art, according to the embodiments of the present invention, there will be changes in the specific implementation methods and application scopes. In summary, the content of this specification should not be understood as limiting the present invention.

Claims

1. A method for preparing fenofibrate impurities, characterized in that: The steps include: (1) an esterification reaction is carried out between the compound of formula I and methyl 2-hydroxyisobutyrate to obtain a compound of formula II; (2) The compound of formula II and isopropanol undergo an ester exchange reaction to obtain a compound of formula III as the target product; The structural compound represented by formula I, the structural compound represented by formula II, and the structural compound represented by formula III are as follows: Formula I Formula II Formula III.

2. The method for preparing a fenofibrate impurity according to claim 1, characterized in that: In the step (1), the compound of formula I and methyl 2-hydroxyisobutyrate undergo an esterification reaction in the presence of a condensing agent and a base; In the step (2), the compound of formula II and isopropanol undergo an ester exchange reaction under alkaline conditions.

3. The method for preparing a fenofibrate impurity according to claim 2, characterized in that: In the step (1), the condensing agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and the base is 4-dimethylaminopyridine; In the step (2), the base is at least one of cesium carbonate and potassium carbonate.

4. The method for preparing a fenofibrate impurity according to claim 1 or 2, characterized in that: In the step (1), the initial concentration of the compound of the structure represented by formula I is 0.1-1 mol / L.

5. The method for preparing a fenofibrate impurity according to claim 2, characterized in that: In the step (1), the amount of the condensing agent used is 1.0 to 3.0 equivalents of the molar amount of the compound of the structure shown in formula I, the amount of the base used is 0.05 to 1.0 equivalents of the molar amount of the compound of the structure shown in formula I, and the amount of methyl 2-hydroxyisobutyrate used is 1.0 to 2.0 equivalents of the molar amount of the compound of the structure shown in formula I.

6. The method for preparing a fenofibrate impurity according to claim 2, characterized in that: In the step (2), the compound of structure represented by formula II is dissolved in isopropanol, the initial concentration of the compound of structure represented by formula II is 0.1-1 mol / L, and the amount of base used is 1.0-4.0 equivalents of the molar amount of the compound of structure represented by formula II.

7. The method for preparing a fenofibrate impurity according to claim 6, characterized in that: In the step (1), the compound of formula I, a condensing agent, a base and a solvent are mixed at room temperature, stirred for 5 to 60 minutes, and finally methyl 2-hydroxyisobutyrate is added, and the mixture is stirred at room temperature for 8 to 24 hours; In the step (2), the compound of the structure represented by formula II is dissolved in isopropanol, a base is added, and the mixture is heated to react to obtain the compound of the structure represented by formula III.

8. The method for preparing a fenofibrate impurity according to claim 7, characterized in that: The solvent in step (1) is dichloromethane.

9. The method for preparing a fenofibrate impurity according to claim 1 or 2, characterized in that: In the step (2), the system is heated to react at a temperature of 30 to 80° C., and the reaction time is 4 to 24 hours.